A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
This study is testing a new personalized cancer vaccine combined with immunotherapy to see if it helps prevent bladder cancer from returning after surgery. Researchers want to find out if this combination keeps patients cancer-free longer and is safe to use.
You may be able to join if you have been diagnosed with a specific type of bladder cancer called urothelial carcinoma and are well enough to handle daily activities. You will also need to provide a sample of your tumor tissue and blood samples so researchers can create your personalized vaccine.
Participants will receive study treatments that may include a personalized vaccine made from their own tumor, immunotherapy drugs, or targeted therapies. Your health and safety will be closely monitored by the medical team throughout the process.
This study has locations in several U.S. cities including Los Angeles, Orlando, and Chicago. The study is currently active but is not looking for new participants right now.
- 1Tests a personalized cancer vaccine made from your own tumor
- 2Aims to prevent bladder cancer from returning after surgery
- 3Combines the vaccine with established immunotherapy treatments
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.